Equibles does not estimate personal net worth.
Get an email with a short summary when BridgeBio Pharma, Inc. publishes a filing, an earnings call transcript or a press release.
Get BBIO alertsThomas Trimarchi is recorded as COO at BridgeBio Pharma, Inc. (BBIO) since July 23, 2024 and CFO at BridgeBio Pharma, Inc. (BBIO). The newest filing on record that lists Thomas Trimarchi as CFO at BridgeBio Pharma, Inc. (BBIO) is dated April 24, 2026. BridgeBio Pharma, Inc. reported in an 8-K filed March 17, 2025 that Thomas Trimarchi was appointed President and Chief Financial Officer (CFO), effective March 17, 2025. BridgeBio Pharma, Inc. reported in an 8-K filed July 23, 2024 that Thomas Trimarchi was appointed President and Chief Operating Officer, effective July 23, 2024. The proxy statement of BridgeBio Pharma, Inc. reports total compensation of $5,832,369 for Thomas Trimarchi in fiscal 2025, including a base salary of $675,589. Disclosed compensation is on record for 2 fiscal years. Thomas Trimarchi has spoken on 1 earnings call and 4 other investor events across 1 company, most recently for BridgeBio Pharma, Inc. on June 9, 2026. BridgeBio Pharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BridgeBio Pharma, Inc. includes Neil Kumar (CEO and Board Member), Charles Homcy (Chairman and Board Member), Brian Stephenson (CFO) and 7 others.
“Thomas Trimarchi, Ph.D. has been appointed President and Chief Financial Officer (CFO) of the Company.”
“Thomas Trimarchi was appointed as the Company's President and Chief Operating Officer, and Neil Kumar, Ph.D. stepped down as President, in each case, effective as of July 23, 2024.”
“Wonderful to be with you in Miami once again. I would start by saying it's an incredibly exciting and energizing moment to be at BridgeBio.”
“Wonderful to be with you in Miami once again. I would start by saying it's an incredibly exciting and energizing moment to be at BridgeBio.”
“I can start and maybe pass over to my fill in some blanks. So BridgeBio is a biotech company that was founded just over 10 years ago now. And we were created to do two things.”
“But I think we've been off to a very good start. The end of this month actually represents one year since launch. You guys have seen our first three-quarter results.”
“I'll now discuss our financial results for the third quarter of 2025. Please note that our commentary on today's call will focus on GAAP financials unless otherwise indicated.”
2024-07-23–present
Start not stated–present
Last confirmed April 24, 2026
Biotechnology · Healthcare
CFO, COO
2024-07-23–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | BridgeBio Pharma, Inc. (BBIO) | President and Chief Financial Officer | $675,589 | $5,832,369 |
| 2024 | BridgeBio Pharma, Inc. (BBIO) | President and Chief Financial Officer | $643,654 | $6,502,058 |
